Immunotherapy with NK cell, rituximab and rhu-GMCSF in non-myeloablative allogeneic stem cell transplantation.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Rituximab (Primary) ; Sargramostim (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 26 Jul 2019 Status changed from active, no longer recruiting to completed.
- 14 May 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 28 Nov 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.